2060357
Last Update Posted: 2015-08-07
Recruiting has ended
All Genders accepted | 18 Years-80 Years |
60 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes (OCT-DES)
The aim of this study is a comparative evaluation of re-endothelailisation of the Integrity Resolute zotarolimus eluting stent (Medtronic) and of the Promus Element erolimus eluting stent (Boston Scientific), in patients with diabetes.
We plan to compare endothelial coverage and neointimal proliferation using OCT and compare this data to published results from conventional stents.
Eligibility
Relevant conditions:
Coronary Artery Disease
Diabetes
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov